科研动态PubMed 摘要

前庭性偏头痛的当代诊断与管理:传统疗法与CGRP靶向疗法的系统综述。

PubMed 学科轮询 · 2026-10-27

完整摘要 · 中文译文

背景:前庭性偏头痛(VM)是复发性发作性眩晕的常见原因,并与复发性前庭症状和偏头痛症状导致的显著失能相关。尽管有多种标准预防性治疗,但其疗效差异很大,而靶向降钙素基因相关肽(CGRP)的新疗法已被确定为潜在治疗方法。本系统综述的目的是评估前庭性偏头痛诊断的最新进展,并比较传统药物治疗与新CGRP靶向治疗的疗效。 方法:进行了系统性文献综述,以寻找评估前庭性偏头痛诊断和药物治疗的研究。纳入的研究包括随机对照试验、观察性研究、比较研究、回顾性分析、横断面研究以及明确或很可能前庭性偏头痛患者的病例报告。对研究特征、诊断方法、治疗干预、临床结局和治疗疗效进行了定性提取和综合。 结果:共纳入21项研究,总计超过12,000名参与者。证据主要包括成人VM人群以及一项大型儿科多中心研究。在成人研究中,参与者主要为中年女性。Bárány学会/ICHD标准被用作诊断评估的主要基础,并结合前庭系统选择性检查和神经影像学以排除其他诊断。conv 预防性治疗与眩晕发作频率、头痛负担及头晕相关残疾的减少相关。抗CGRP治疗,包括依瑞奈尤单抗(erenumab)、弗瑞奈尤单抗(fremanezumab)、加卡奈珠单抗(galcanezumab)、瑞美吉泮(rimegepant)和乌布吉泮(ubrogepant),与眩晕发作频率、每月头晕天数、残疾评分、头痛结局及患者报告的生活质量方面具有临床意义的改善相关。 结论:当前证据支持采用多模式方法对前庭性偏头痛进行临床评估,传统预防性治疗和CGRP靶向治疗均在前庭及偏头痛相关结局方面显示出获益。CGRP靶向治疗代表了一种有前景的新兴治疗选择,尤其适用于症状持续或难治的患者。然而,有限的随机证据以及与常规治疗直接头对头比较的匮乏,使得无法就其比较有效性得出确切结论。系统综述注册号:CRD420261427685。

完整摘要 · 英文原文

BACKGROUND: Vestibular migraine (VM) is a common cause of recurrent episodic vertigo, and it is associated with significant disability from recurrent vestibular and migraine symptoms. While there are a number of standard preventive treatments, their effectiveness is quite variable, and new treatments which target calcitonin gene-related peptide (CGRP) have been identified as potential treatments. The purpose of this systematic review was to assess the state of the art in the diagnosis of vestibular migraine and to compare the efficacy of conventional pharmacological treatments with the new CGRP-targeted treatments. METHODS: A systematic literature review was performed to find studies that assessed the diagnosis and pharmacological treatment of vestibular migraine. Randomized controlled trials, observational studies, comparative studies, retrospective analysis, cross-sectional studies, and case reports of patients with definite or probable vestibular migraine were included. Study characteristics, diagnostic methods, therapeutic interventions, clinical outcomes, and treatment efficacy were qualitatively extracted and synthesized. RESULTS: 21 studies were included with a total of over 12,000 participants. The evidence comprised predominantly adult VM populations together with one large pediatric multicenter study. Among adult studies, participants were predominantly middle-aged women. The Bárány Society/ICHD criteria were used as a primary basis for the diagnostic evaluation, with selective tests of the vestibular system and neuroimaging to rule out alternative diagnoses. conventional preventive therapies were associated with reductions in vertigo frequency, headache burden, and dizziness-related disability. Anti-CGRP therapies including erenumab, fremanezumab, galcanezumab, rimegepant, and ubrogepant, were associated with clinically meaningful improvements in vertigo frequency, monthly dizziness days, disability scores, headache outcomes, and patient-reported quality of life. CONCLUSION: A multimodal approach to the clinical evaluation of vestibular migraine is supported by current evidence, and both traditional preventive treatments and CGRP-targeted treatments have demonstrated benefit across vestibular and migraine-related outcomes. CGRP-targeted therapies represent a promising emerging therapeutic option, particularly for patients with persistent or refractory symptoms. however, the limited randomized evidence and scarcity of direct head-to-head comparisons with conventional therapies preclude firm conclusions regarding their comparative effectiveness. Systematic review registration: identifier: CRD420261427685.

English
Contemporary diagnosis and management of vestibular migraine: a systematic review of conventional and CGRP-targeted therapies.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界